Name: Stem Cells: Worldwide Markets for Transplantation and Cord Blood Banking (Projections for Stem Cell Use in Cancer, Alzheimer&rsquo;s, Diabetes, Arthritis and Other Diseases)
SKU: KLI6490034
Availability: InStock

Description

There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells also have value as a research tool, as their in vitro study would allow scientists to learn more about the function of various organs and the development of particular diseases; stem cells may also eventually permit drug developers to test emerging therapies on diseased cells.

For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the pharmaceutical market. New scientific developments and recent changes in the U.S. Federal government’s policy towards stem cells have made this potential more relevant. Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:

Stem Cells in Drug Development
Stem Cells in Cord Blood Banking
Stem Cell Therapeutics

The potential of stem cell therapeutics is provided, broken down by disease:

Cardiovascular disease
Lung disease
Tooth disease
Arthritis
Wrinkles/aging skin
Incontinence
Osteoporosis
Diabetes
Cancer
Bladder disease
Infertility
Orthopedics
Alzheimer’s disease
Burns (severe)
Lupus
Parkinson’s disease
Liver failure
Multiple sclerosis
Critical limb ischemia
Intestinal disease
Sickle cell disease
Multiple myeloma
NH Lymphoma
Leukemia

The following trends are discussed in this report:

Ethical Questions
U.S. – State and Federal Initiatives
Research Funding
Cord Blood Initiatives
International Initiatives
Stem Cell Patents
Other Healthcare Regulations

All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.

For Kalorama’s take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information’s Key Point Blog at
http://kaloramakeypoint.blogspot.com/

CHAPTER ONE: EXECUTIVE SUMMARY

Scope and Methodolgy
Introduction
Current Stem Cell Therapies
Developmental Stem Cell Therapies
Issues In Stem Cell Research
Stem Cell Forecasts

CHAPTER TWO: INTRODUCTION

The Promise of Stem Cells In Medical Treatment
Types of Stem Cells
- Embryonic Stem Cells
- Adult Stem Cells
- Cord Blood Stem Cells
Stem Cell Harvesting
Embryonic Stem Cells
Therapeutic Cloning
Unfertilized Eggs
Adult Stem Cells
Leukapheresis
Peripheral Blood
Cord Blood Stem Cells
Transplantation Approaches
- Autologous Transplantation
- Allogenic Transplantation
- Transplantation Procedures
Cancerous Stem Cells
Other Harmful Stem Cells
Stem Cells in Drug Development
Stem Cell Therapeutics
Stem Cells Targeting Drugs
Stem Cell Generated Organs

CHAPTER THREE: CURRENT STEM CELL THERAPIES

Cancer
Leukemia
Gene Therapy
Multiple Myeloma
Non-Hodgkin’s Lymphoma
Non Cancerous Diseases
Aplastic anemia
Immunodeficiency
Lupus
Sickle Cell Disease
Other Conditions

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

Alzheimer’s Disease
Arthritis
Bladder Disease
Burns
Cancer
Cardiovascular Conditions
Critical Limb Ischemia
Diabestes
Esophagal Disease
Incontinence
Infertility
Intestinal Disease
Liver Failure
Lung Disease
Multiple Sclerosis
Orthopedics
Osteoporosis
Parkinson’s Disease
Sickle Cell Disease
Tooth Disease
Wrinkles/Aging Skin

CHAPTER FIVE: STEM CELL FORECASTS

Best Case
- Stem Cell Therapeutics
- Umbilical Cord Blood Banking
- Fees Related to Drug Development
Most Likely Case
- Stem Cell Therapeutics
- Umbilical Cord Blood Banking
- Fees Related to Drug Development
Worst Case
- Stem Cell Therapeutics
- Umbilical Cord Blood Banking
- Fees Related to Drug Development

CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

Ethical Questions
U.S. – State and Federal Initiatives
- Research Funding
- Federal Funding
- State Funding
- Cord Blood Initiatives
- International Initiatives
Stem Cell Patents
Other Healthcare Regulations

LIST OF EXHIBITS CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1 Total Market for Stem Cell Technologies in $ Millions, 2010 – 2020
Table 1-2 Stem Cell Therapeutics Market in $ Millions, 2010 – 2020
Table 1-3 Total Market for Cord Blood Banking Fees in $ Millions, 2010 – 2020
Table 1-4 Total Market for Stem Cell Drug Development Technologies in $ Millions, 2010 – 2020
Figure 1-1 Total Market for Stem Cells – Most Likely Case in $ Millions, 2010 – 2020

CHAPTER TWO: INTRODUCTION

Table 2-1 Established and Emerging Artificial Organ Products by Market Segment, 2010

CHAPTER THREE: CURRENT STEM CELL THERAPIES

Table 3-1 Types of Leukemia, 2011

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

Table 4-1 Global Disease Populations Addressed by Potential Stem Cell Therapies, 2011
Table 4-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
Table 4-3 Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2010 and 2020
Table 4-4 Features and Types of Urinary Incontinence, 2011
Table 4-5 Types and Causes of Male Infertility, 2011
Table 4-6 Common Diseases of the Lungs, 2011

CHAPTER FIVE: STEM CELL FORECASTS

Table 5-1 Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2011
Table 5-2 Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 – 2020
Table 5-3 Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 – 2020
Table 5-4 131 Best Case: Cord Blood Banking Revenues in $ Millions, 2007 – 2020
Table 5-5 Best Case: Stem Cell-Based Drug Development Technology Fees, 2010 – 2020
Table 5-6 Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 – 2020
Table 5-7 Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 – 2020
Table 5-8 Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 – 2020
Table 5-9 Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2010 – 2020
Table 5-10 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010 – 2020
Table 5-11 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 – 2020
Table 5-12 Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 – 2020
Table 5-13 Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 – 2020
Table 5-14 Worst Case: Cord Blood Banking Revenues in $ Millions, 2010-2020
Table 5-15 Worst Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010-2020
Table 5-16 Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions 2010-2020